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http://dx.doi.org/10.1016/j.ccr.2013.05.004SUMMARYWe used an in vivo small hairpin RNA (shRNA) screening approach to identify genes that are essential for
MLL-AF9 acutemyeloid leukemia (AML).We found that Integrin Beta 3 (Itgb3) is essential for murine leukemia
cells in vivo and for human leukemia cells in xenotransplantation studies. In leukemia cells, Itgb3 knockdown
impaired homing, downregulated LSC transcriptional programs, and induced differentiation via the intracel-
lular kinase Syk. In contrast, loss of Itgb3 in normal hematopoietic stem and progenitor cells did not affect
engraftment, reconstitution, or differentiation. Finally, using an Itgb3 knockout mouse model, we confirmed
that Itgb3 is dispensable for normal hematopoiesis but is required for leukemogenesis. Our results establish
the significance of the Itgb3 signaling pathway as a potential therapeutic target in AML.Significance
Effective therapy for acute myeloid leukemia (AML) requires the
microenvironment that supports the survival of both normal a
screens, we identified molecules that are essential for leukem
meric partner, integrin alpha v (Itgav); and downstream signalin
tial mediator of Itgb3 activity in AML. Loss of Itgb3 or Syk ind
stem cell gene-expression signatures. In contrast, genetic inac
lighting the potential of targeting Itgb3 signaling to treat AML.elimination of leukemia cells residing in the bone marrow, a
nd malignant hematopoietic cells. In a series of in vivo RNAi
ia cells in vivo, including integrin beta 3 (Itgb3); its heterodi-
g molecules. We found Syk phosphorylation to be an essen-
uced differentiation and decreased expression of leukemia
tivation of Itgb3 did not impair normal hematopoiesis, high-
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Acute myeloid leukemia (AML) is characterized by increased
proliferation and impaired differentiation of hematopoietic
stem and progenitor cells (HSPCs). With current treat-
ments, the 5-year overall survival in adult AML is less than
20% and has improved only modestly in the past 30 years
(Maynadie´ et al., 2011). The development of novel thera-
pies with greater efficacy and decreased toxicity requires
the identification of specific dependencies in leukemia cells
that are absent in normal HSPCs in vivo (Gilliland et al.,
2004).
Leukemia stem cells (LSCs) are a self-renewing sub-
population that is capable of initiating the disease upon trans-
plantation into healthy recipients (Lapidot et al., 1994). LSCs
reside in an in vivo microenvironment, as do normal
HSPCs (Scadden, 2007). Increasing evidence indicates that
the niche for malignant cells can influence disease initiation
(Raaijmakers et al., 2010), lineage decisions (Wei et al.,
2008), cellular localization, and response to chemotherapy
(Ishikawa et al., 2007). Successful strategies to target the
interaction of LSCs with the microenvironment using both
small molecules (Parameswaran et al., 2011; Zeng et al.,
2009) and biologics (Chao et al., 2010; Jin et al., 2006)
have been reported.
Monotypic cell culture lines used in some traditional
high-throughput drug-discovery efforts may not reflect the
primary disease from which they were derived (Drexler
et al., 2000; Sharma et al., 2010) and thus may not be useful
for probing important interactions between primary leukemia
cells and the hematopoietic niche or identifying which of
these interactions are selectively required for leukemia cells
relative to normal HSPCs. Indeed, a number of ‘‘nontradi-
tional’’ screens have identified important modulators of dis-
ease biology (Guzman et al., 2005; North et al., 2007; Yeh
et al., 2009).
Pooled in vivo RNAi screens offer a strategy for identifying
novel therapeutic targets for leukemia in their physiologic
microenvironment. In this approach, primary leukemia cells
that are enriched for stem cell activity and are capable of
generating leukemia in mice are infected with a pool of lentivi-
ruses expressing small hairpin RNAs (shRNAs). Transduced
cells are transplanted into recipient mice, where they engraft
and grow in the host microenvironment. The quantitative repre-
sentation of each shRNA in the pool of cells prior to transplan-
tation and at subsequent time points can be determined by
using massively parallel sequencing, highlighting genes that
are essential for malignant cells (Luo et al., 2008; Mendes-
Pereira et al., 2011).
We employed this approach to find therapeutic targets in
primary murine and human AML cells using the MLL-AF9
mouse model of human leukemia. A number of MLL translo-
cations, including MLL-AF9 and MLL-ENL, have been shown
in mouse models to transform committed hematopoietic pro-
genitors (Cozzio et al., 2003; Krivtsov et al., 2006). We per-
formed a series of in vivo shRNA screens to identify genes
that are selectively essential for leukemia cells compared
with normal HSPCs, and to explore downstream signaling
molecules.46 Cancer Cell 24, 45–58, July 8, 2013 ª2013 Elsevier Inc.RESULTS
Pooled In Vivo shRNA Screening of Primary Murine
Leukemia
To achieve a robust pooled in vivo shRNA screen in primary AML
cells, we sought to use a model with labeled leukemia cells, an
established cell-surface marker phenotype of LSCs, a short
latency, and a high penetrance. To this end, we introduced the
MLL-AF9 oncogene via retroviral transduction into flow-sorted
granulocyte-monocyte progenitor cells (GMPs) fromActin-dsRed
transgenic mice, enabling rapid identification of leukemic cells
within wild-type tissue. Previous studies have shown that expres-
sion ofMLL-AF9 in normalGMPs is sufficient to create an aggres-
sive, transplantable myeloid leukemia with functionally defined
LSCs that display an immunophenotype similar to that of normal
GMPs (Linlo, Sca-1, c-Kit+, FcgRIIhi, and CD34hi) (Krivtsov et al.,
2006). We further enriched for stem cell activity by serially trans-
planting the leukemias through secondary, tertiary, and quater-
nary recipients, generating fluorescently labeled leukemias with
100%penetrance (FigureS1Aavailableonline).Wenotedpredict-
able and reproducible engraftment of leukemia cells in the bone
marrowand spleen of recipientmice after transplant (Figure S1B).
We performed a primary screen using a pool of lentiviruses,
each of which expressed one of 1,352 shRNAs, targeting 268
genes plus 66 control shRNAs that are not homologous to the
sequence of any murine genes (Figure 1A). The targets include
known and candidate cancer-associated genes and genes that
were discovered in previous unbiased RNAi screens (Table
S1). Sorted leukemia cells (Figure 1B) from quaternary transplant
MLL-AF9-dsRedmice were transduced with the lentiviral shRNA
pool and transplanted into sublethally irradiated recipients. In
addition, an aliquot of leukemia cells was plated onto OP9 stro-
mal cells, a well-established murine, bone-marrow-derived stro-
mal cell line that is capable of supporting primary HSPCs for
many weeks in vitro in the absence of cytokine supplementation
(Nakano et al., 1994). Using massively parallel sequencing of
PCR-amplified shRNA sequences from genomic DNA, we quan-
tified the relative representation of each shRNA in the infected
leukemia cells immediately after infection, and in cells harvested
2 weeks later from the bone marrow, spleen, and in vitro culture.
We selected 60 candidate genes targeted by at least two
shRNAs that were most highly depleted over 2 weeks (candidate
genes that are required for leukemia cells), and 15 genes
targeted by at least two shRNAs that were most increased
over 2 weeks in vivo or in vitro.
We systematically retested all 75 candidate genes in an in vivo
validation screen (Figure 1C), achieving 20-fold higher coverage
of leukemia cells per shRNA than in the primary screen and high
interreplicate reproducibility (Figures 1D and S1C–S1G). The
relative representations of each shRNA after 2 weeks in the
bone marrow and spleen were highly correlated (R2 = 0.85; Fig-
ure 1C), demonstrating the reproducibility of the screen and the
biological similarity of leukemia cells in these organs. The top hits
demonstrate that the shRNA screen highlights biologically rele-
vant molecules (Figure 1E). Consistent with the recently reported
requirement of b-catenin in MLL-AF9 LSCs (Wang et al., 2010;
Yeung et al., 2010), all three shRNAs targeting b-catenin were
depleted by >20-fold (Figure 1F), and shRNAs targeting Apc,
a negative regulator of b-catenin activity, were enriched in
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Figure 1. Pooled In Vivo shRNA Screening
of Primary Leukemic Cells Identifies Itgb3
as a Mediator of Leukemia Progression
(A) The primary screen (green) was performed
using LSCs isolated from quaternary transplant
leukemia. The in vivo arm was performed in five
replicate mice, and the in vitro arm was performed
on the OP9 stromal cell line in six replicates. The
primary screen hits were retested in five separate
subpools with five replicates per mouse in the
validation screen (red). T0 is the time point 24 hr
after infection.
(B) Primary LSCs (Hoechstlo dsRed+ c-Kithi CD34+
FcgRIIhi) driven by the MLL-AF9 oncogene used
for screening were isolated from the bone marrow
of moribund quaternary transplant leukemic mice.
(C) A scatterplot of the change in shRNA repre-
sentation in the validation screen after in vivo
growth shows high concordance between the
bonemarrow and spleen compared with input. For
genes highlighted in blue, at least two shRNAs
were depleted by 20-fold in either the bone
marrow or spleen.
(D) In a heatmap depiction of the validation
screen, individual shRNAs (rows) in each replicate
(columns) are shown in deep red for the highest
number of reads and in blue for low numbers of
reads.
(E) Multiple shRNAs targeting positive control
genes were depleted by 20-fold in the validation
screen.
(F–H) The prevalence of test shRNAs (colored
lines) and control shRNAs (gray lines) over time in
the validation screen is shown for Ctnnb1 (F), Apc
(G), and Itgb3 (H).
See also Figure S1 and Tables S1 and S2.
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Leukemia-Specific Dependence on Itgb3 Signalingleukemia cells after 2 weeks (Figures 1G and S1H). At least two
shRNAs per gene were depleted for additional genes known to
be required for MLL-AF9 leukemia (Mef2c and Ccna1) (Ekberg
et al., 2005; Krivtsov et al., 2006; Liao et al., 2001), genes univer-
sally required for cell survival (Ube2j2 and Utp18) (Luo et al.,
2008), genes reported to be essential in other AML models
(Hmgb3) (Petit et al., 2010; Somervaille et al., 2009; Wang
et al., 2005), and Myb, a gene that is important for LSC and
HSPC survival (Lieu and Reddy, 2009; Somervaille et al., 2009).
The performance of shRNAs targeting these genes demon-
strates that our in vivo screen is capable of detecting the activity
of genes with biological relevance for MLL-AF9 leukemia cells.
Integrin Beta 3 Is Essential for Leukemia Cells
The top three hits from the validation screen were two positive
controls with established importance in MLL-AF9 leukemia,Cancer Cell 24,Ctnnb1 and Hmgb3 (Somervaille et al.,
2009; Wang et al., 2010), and Itgb3, en-
coding Integrin Beta 3. In all cases, three
independent shRNAs were depleted
by >20-fold over 2 weeks (Figures 1F
and 1H; Table S2). Integrins mediate
many cellular processes and interact
with multiple components of the bone
marrow, including fibronectin, vitro-nectin, osteopontin, and bone sialoprotein, raising the possibil-
ity that Itgb3 plays a role in the interaction of leukemia cells with
the microenvironment (Seiffert, 1996; Stier et al., 2005; Zhang
et al., 2009). The previously reported Itgb3 germline knockout
mouse has normal peripheral blood counts, aside from platelet
defects resulting from disruption of the Itgb3/Itga2b (GPIIb/IIIa)
receptor (Hodivala-Dilke et al., 1999), and the conditional
knockout animal has no hematopoietic defect in the primary
recipient and a mild defect in reconstitution in the secondary
recipient (Umemoto et al., 2012). Additionally, Glanzmann’s
thrombasthenia is a human disorder of impaired platelet activa-
tion that results from mutations in either ITGB3 or ITGA2b,
which together form the GPIIb/IIIa receptor on platelets (Nurden
et al., 2011). Critically, aside from the platelet activation
defect, patients with biallelic ITGB3 mutations do not have a
bone-marrow failure phenotype, highlighting the potential45–58, July 8, 2013 ª2013 Elsevier Inc. 47
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Figure 2. Itgb3 Knockdown Impairs
Leukemia Cell Growth and Survival In Vivo
(A) Itgb3 RNA and protein levels were assessed in
Ba/F3 cells after infection with Itgb3 or control
shRNAs.
(B and C)Ctnnb1 (B), Itgb3 (C), and control (shLuc)
shRNAs were cloned into GFP-expressing lenti-
viral vectors, transduced into primary leukemias,
and transplanted, and the percentage of GFP+
cells was assessed before transplant and in the
bone marrow after 2 weeks in vivo (**p < 0.01).
Normalized GFP reflects the ratio of GFP at a given
time point to the level immediately after infection.
(D) Primary leukemia cells carrying pMIG-
Itgb3Rescue (GFP+) were enriched in the bone
marrow of sublethally irradiated recipients over
2 weeks in the presence of Itgb3 but not control
shRNAs (p < 0.05, significance determined by
two-way ANOVA analysis).
(E) Leukemia cells (n = 50,000) carrying Itgb3 or
control shRNAs were transplanted into sublethally
irradiated mice and monitored for time until death.
Mice transplanted with cells expressing Itgb3
shRNAs had a significantly prolonged survival,
as determined by Kaplan-Meier survival analysis
(n = 4 mice per group). Error bars represent ±SEM.
See also Figure S2.
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Leukemia-Specific Dependence on Itgb3 Signalingdispensability of ITGB3 in long-term hematopoietic stem cell
maintenance and function.
We first confirmed the functional effects of Itgb3 and Ctnnb1
shRNAs. We verified that primary murine leukemia cells express
Itgb3, and that all three shRNAs targeting Itgb3 and Ctnnb1
effectively decreased expression of their target gene (Figures
2A, S2A, and S2B). To track the shRNA-carrying leukemia cells
by flow cytometry, we inserted the Ctnnb1, Itgb3, and control
(shLuc) shRNAs into a lentiviral vector that coexpresses GFP.
We transduced leukemia cells with these shRNA-lentiviruses
expressing GFP, transplanted them into sublethally irradiated
recipients, and followed the proportion of GFP+ leukemia cells
over time (Figure S2C). In contrast to the pooled screening
approach, each mouse was transplanted with leukemia cells
transduced with lentivirus expressing a single shRNA. Consis-
tent with the results of the pooled screen, the proportion of
leukemia cells expressing Ctnnb1 and Itgb3 decreased dramat-
ically over 14 days in vivo, whereas the percentage of leukemia
cells expressing the control shRNA was stable in the bone
marrow (Figures 2B and 2C) and spleen (Figures S2D and
S2E). We also found that after 7 days of growth in vivo, leukemia
cells carrying Itgb3 shRNAs continued to have decreased cell-
surface expression of Itgb3 (Figure S2F).
Of note, despite homing and engrafting in the bone marrow at
day 6, the disease burden of leukemia cells carrying Itgb3
shRNAs progressively declined over time, reflecting the
continued activity of the shRNAs in cells in the niche. To evaluate
the possibility that the observed phenotype was due solely to48 Cancer Cell 24, 45–58, July 8, 2013 ª2013 Elsevier Inc.impaired homing of the cells to the bone
marrow, we assessed the activity of the
Itgb3 shRNAs in an ex vivo assay. Primary
leukemia cells were harvested, infectedwith Itgb3 or control shRNAs, and then grown in isolation with
murine IL-3 or in coculture with OP9 cells, murine bone-marrow
stromal cells that were previously shown to support ex vivo
growth of HSPCs (Nakano et al., 1994) and to be capable of
supporting primary leukemia cells in the absence of cytokine
supplementation. Regardless of the culturing condition used,
the leukemia cells carrying Itgb3 shRNAs were depleted over
time, reflecting the fact that these shRNAs can act in a hom-
ing-independent fashion (Figure S2G). Importantly, we did not
observe any appreciable effect of lentiviral infection on cell-
surface Itgb3 expression (Figure S2H).
Because any individual shRNA might produce off-target
effects that influence the observed phenotypes, we confirmed
the specificity of the Itgb3 shRNAs. We designed an Itgb3 com-
plementary DNA (cDNA; Itgb3Rescue) with at least six silent muta-
tions at each of the shRNA-binding sites and inserted the cDNA
into the pMSCV-IRES-GFP (pMIG) retroviral backbone. Expres-
sion of pMIG-Itgb3Rescue resulted in high cell expression of Itgb3
on primary leukemia cells in vivo and did not significantly alter the
growth characteristics of the leukemia cells after 2 weeks in
either the bone marrow or spleen (Figures S2I and S2J). In Ba/
F3 cells, introduction of pMIG-Itgb3Rescue resulted in high levels
of Itgb3 expression that was maintained despite expression of
Itgb3 shRNAs (Figure S2K). Leukemia cells were serially trans-
duced with pMIG-Itgb3Rescue and either Itgb3 or control shRNAs
coexpressing the puromycin resistance gene, selected in puro-
mycin for 2 days, and transplanted into recipient mice (Fig-
ure S2L). GFP+ cells carrying the Itgb3Rescue vector increased
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Figure 3. The Itgb3/Itgav Heterodimer Is
Required for Murine and Human Leukemia
Growth In Vivo
(A and B) Cell-surface expression of Itgav on un-
manipulated primary murine leukemia cells (A) or
primary cells infected with Itgb3-20 or control
shRNAs after 7 days in vivo (B) was determined by
flow cytometry.
(C and D) Itgav shRNAs decrease Itgav transcript
levels (C) and decrease leukemia cell growth after
2 weeks in vivo as assessed by the percentage of
GFP+ cells (D).
(E) Two ITGB3 shRNAs were strongly depleted
from M9 cells in the bone marrow (blue) and
spleen (red) after 3 weeks of growth in NSG mice.
(F) ITGB3 shRNAs impair the in vivo growth of both
cytogenetically normal (green) and MLL-re-
arranged (red) primary human AML cells as as-
sessed by shRNA representation in the bone
marrow and spleen of NSG recipient mice after 6
(MLL-rearranged) or 8 (normal cytogenetics)
weeks. **p < 0.01. Error bars represent ±SEM.
See also Figure S3.
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Leukemia-Specific Dependence on Itgb3 Signalingin the leukemias coexpressing the Itgb3 shRNAs, but not in the
leukemias expressing a control shRNA over 2 weeks in vivo (Fig-
ure 2D), reflecting the ability of Itgb3Rescue to abrogate the effects
of the Itgb3 shRNAs. Confirming our prior results, the lack of
GFP+ cell expansion in the Itgb3Rescue plus shLuc control dem-
onstrates that Itgb3Rescue alone does not change the growth
properties of the leukemia cells.
We next sought to determine whether knockdown of Itgb3
would confer a survival advantage to recipient mice. Sublethally
irradiated recipient mice were transplanted with 50,000 leuke-
mia cells, all of which expressed Itgb3 shRNAs, in contrast to
the GFP-tracking experiment in which only a subset of cells ex-
pressed GFP (Figure S2C). Mice that were transplanted with
leukemia cells expressing Itgb3 shRNAs lived significantly
longer than control mice (Figure 2E). These experimentsCancer Cell 24,demonstrate that Itgb3 shRNAs effec-
tively impair leukemia growth in vivo.
The Heterodimer Itgb3/Itgav Is
Required for Leukemia Cell
Survival
Because Itgb3 heterodimerizes with Itgav
in myeloid cells (Savill et al., 1990), we
hypothesized that knockdown of Itgav
would phenocopy knockdown of Itgb3,
providing further evidence of the function
of Itgb3 in leukemia. We first confirmed
the coexpression of Itgav and Itgb3 on
leukemia cells in our model by flow
cytometry (Figures 3A and S3A). Consis-
tent with the known interaction of Itgb3
and Itgav, knockdown of Itgb3 with
shRNA Itgb3-20 decreased Itgav cell-
surface expression after 7 days in vivo
(Figure 3B). Furthermore, using our
GFP-tracking approach, we found thatleukemia cells expressing either of two shRNAs that suppress
Itgav (Figure 3C) were depleted from the bone marrow and
spleen after 2weeks of growth in vivo relative to a control shRNA,
demonstrating that Itgav, like Itgb3, is required for leukemia cells
(Figures 3D and S3B).
ITGB3 Is a Target in Human Leukemia
To establish the relevance of ITGB3 for human disease, we
examined the expression and functional importance of ITGB3
in human AML. Using flow cytometry, we found examples of
ITGB3/ITGAV expression on primary human samples of both
MLL-rearranged and non-MLL-rearranged AML (Figure S3C).
Next, we assessed the functional importance of human ITGB3
in M9 cells, leukemia cells derived from umbilical cord blood
cells transduced with the MLL-ENL oncogene (Barabe´ et al.,45–58, July 8, 2013 ª2013 Elsevier Inc. 49
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Leukemia-Specific Dependence on Itgb3 Signaling2007). M9 cells can either be passaged in vitro or transplanted
into immunodeficient mice, resulting in leukemia. We generated
a pool of lentiviral shRNAs targeting the human counterparts of
the genes that scored in our murine screen. Following transduc-
tion with the pooled lentivirus, M9 cells were transplanted into
immunodeficient NOD-SCID/IL2Rg/ (NSG) recipient mice
and harvested after 21 days. The representation of shRNAs in
the bone and spleen was assessed by massively parallel
sequencing. As with the murine screens, the data were highly
reproducible between replicates and between the bone marrow
and spleen (Figure S3D). Both of the validated ITGB3 shRNAs
tested were depleted by 20-fold in the spleens and bone marrow
of mice transplanted with M9 cells relative to control shRNAs,
replicating the results from our murine screen in human cells
with an independent set of shRNAs (Figure 3E).
To evaluate the functional relevance of ITGB3 for primary
human disease, we performed xenotransplantation studies
with primary human AML samples expressing ITGB3 or control
shRNAs. We examined two primary AML samples: one from a
patient with cytogenetically normal AML and one from a patient
with MLL-rearranged AML. We transduced a pool of lentiviruses
with human ITGB3 and control shRNAs into the primary leukemia
cells. After 24 hr, half of the cells were harvested for processing
and half were transplanted into immunodeficient NSG mice. We
monitored the mice for engraftment and progression of disease
by peripheral blood hCD45 analysis. Bone marrow and spleens
were harvested 6 weeks after transplant for the MLL-rearranged
AML and 8 weeks for the cytogenetically normal AML. The rep-
resentation of shRNAs was assessed by massively parallel
sequencing. We found that two independent ITGB3 shRNAs,
both of which effectively decrease ITGB3 expression, impaired
primary leukemia cell growth of both samples by at least
10-fold in the bone marrow and spleens of recipient mice (Fig-
ures 3F and S3E). In aggregate, these findings demonstrate
that, at least for a subset of primary human leukemia, ITGB3 is
expressed on the cell surface and is functionally essential in vivo.
Knockdown of Itgb3 Does Not Impair Normal HSPC
Function In Vivo
The therapeutic opportunity for targeting Itgb3 in leukemia de-
pends on the selective importance of Itgb3 for leukemia cells
relative to normal HSPCs. In wild-type mice, we found Itgb3
expression on stem, progenitor, and mature myeloid cells.
Expression was higher in stem cells (Linlo Sca-1+ c-Kit+
CD48lo – LSK CD48lo) compared with progenitor cells (LSK
CD48hi; Figures 4A and S4A). Among progenitor cells, expres-
sion was highest in GMPs, which share the immunophenotype
of the LSC population in the MLL-AF9model (Figure 4B; Krivtsov
et al., 2006). Mature myeloid cells (Mac1+ Gr1+) had higher ex-
pression than immature myeloid cells (Mac1Gr1; Figure S4B).
We examined the functional effect of acute Itgb3 loss by trans-
ducing murine LSK cells with Itgb3 or control shRNAs (Figures
4C and S4C) and transplanting the cells into lethally irradiated re-
cipients. Because the infection efficiency was not 100%, only a
portion of the LSKs expressed the shRNAs (and thus were
GFP+); therefore, the experimental setup represents a competi-
tive transplant in which, within each mouse, the LSKs carrying
an shRNA competed against the LSK that did not carry an
shRNA. We found no significant difference between normal cells50 Cancer Cell 24, 45–58, July 8, 2013 ª2013 Elsevier Inc.expressing Itgb3 or control shRNAs, based on the percentage of
GFP+ peripheral blood cells over 24 weeks. This finding stands in
striking contrast to the profound in vivo growth inhibition medi-
ated by the same Itgb3 shRNA in leukemia cells (Figures 2C
and 2E). We also performed peripheral blood lineage analysis
at 24 weeks to determine whether the Itgb3 shRNA had any
effect on differentiation. We found there was no significant differ-
ence in the levels of T, B, or myeloid cells between the two
groups (Figure 4D), suggesting that Itgb3 knockdown does not
impair HSPC differentiation in the transplant model.
Itgb3 Knockdown Impairs Leukemia Cell Homing and
Induces Differentiation
Given the role of integrins in multiple cellular processes,
including proliferation and homing, we sought to determine the
mechanism of leukemia cell depletion following Itgb3 knock-
down. First, using Hoechst staining, we found no differences in
the cell-cycle states of primary leukemia cells expressing
Itgb3-17, Itgb3-20, or control shRNAs after 4 days (Figure S5A).
We next examined whether decreased expression of Itgb3 alters
primary leukemia cell homing. Primary leukemia cells were in-
fected with Itgb3 or control shRNAs, transplanted into suble-
thally irradiated recipients, and harvested from the long bones
of mice after 16 hr. We found no difference in the representation
of shRNA-carrying leukemia cells between the two groups (Fig-
ure S5B), implying that Itgb3 knockdown does not cause a gross
defect in bone-marrow localization after transplant. Next, we
used live in vivo imaging of the murine calvarial bone marrow
(Fujisaki et al., 2011) to investigate the possibility that, despite
the ability of cells to travel to the bone marrow after Itgb3 knock-
down, there may be a defect in homing to the endosteum.
Leukemia cells that were transduced with either Itgb3-20 or con-
trol shRNAs were isolated, stained with DiD (a membrane-bound
fluorescent dye), and transplanted into lethally irradiated recip-
ient mice. After 24 hr, identical volumes of calvarial bone marrow
were imaged using intravital two-photon confocal microscopy.
Compared with leukemia cells transduced with control shRNA,
significantly fewer leukemic cells transduced with the Itgb3-20
shRNA were anchored near the endosteal surface (Figures 5A
and S5C), demonstrating that Itgb3 contributes to homing of
leukemia cells in vivo.
We next examined the effect of Itgb3 knockdown by gene-
expression profiling. Strikingly, four of the top 20 most upregu-
lated probe sets in the Itgb3 knockdown samples encoded
myeloperoxidase and lysozyme, two highly specific markers
for myeloid maturation (Figure 5B). Gene set enrichment analysis
(GSEA) (Subramanian et al., 2005) confirmed that, compared
with a control shRNA, the Itgb3 knockdown samples had signif-
icantly higher expression of a series of published myeloid differ-
entiation signatures (Hahn et al., 2009; Krivtsov et al., 2006;
Novershtern et al., 2011) and lower expression of a series of
LSC signatures (Gal et al., 2006; Somervaille et al., 2009; Fig-
ure 5C; Table S3).
In agreement with the GSEA results, compared with a control
shRNA, leukemia cells expressing Itgb3 shRNAs had signifi-
cantly lower levels of c-Kit (Figures 5D and S5D), a cell-surface
protein that marks populations most enriched for LSCs (Krivtsov
et al., 2006). Furthermore, histopathological analysis of cellular
morphology following Itgb3 knockdown revealed darker nuclei,
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Leukemia-Specific Dependence on Itgb3 Signalingdecreased nuclear/cytoplasmic ratios, and increasedmonocytic
morphologic changes, consistent with myeloid differentiation
(Figure 5E). In contrast to themyeloid differentiation and LSC sig-natures, Itgb3 knockdown did not alter three previously pub-
lished b-catenin gene signatures (Bild et al., 2006; Liberzon
et al., 2011; Onder et al., 2008; Figure S5E).Cancer Cell 24, 45–58, July 8, 2013 ª2013 Elsevier Inc. 51
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(legend continued on next page)
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Leukemia-Specific Dependence on Itgb3 SignalingWe then examined the activity of human ITGB3 shRNAs in two
human AML cell lines, HL-60 and U937, which are canonical
models of differentiation therapy in AML. After confirming
expression of ITGB3 and activity of ITGB3 shRNAs in both cell
types (Figure 5F), we found that ITGB3 knockdown induced
morphological evidence of differentiation (Figure 5G) and
increased expression of a gene-expression signature of myeloid
differentiation. This was comparable to the effects of all-trans-
retinoic acid (ATRA), detected by multiplexed ligation-mediated
amplification and detection of amplicons on fluorescent beads
as previously described (Hahn et al., 2009; Figures 5H and
S5F). Both ITGB3 shRNAs also dramatically increased cell-
surface expression of the mature myeloid markers CD14 and
CD11b in HL-60 and U937 cells (Figures 5I and S5G), consistent
with myeloid differentiation.
Identification of Mediators of Itgb3 Signaling
in Leukemia
Having established that Itgb3 knockdown selectively targets
leukemia cells, impairs homing, and induces differentiation, we
sought to determine whether mediators of Itgb3 signaling are
also essential for MLL-AF9 transformed cells. Itgb3 signaling
has been studied in platelets and other cell types, but not in
leukemia (Kasirer-Friede et al., 2004; Kim et al., 2009). We
sought to identify critical mediators of Itgb3 signaling in our
primary mouse model using a comprehensive functional
approach.We therefore systematically analyzed known pathway
members with an additional pooled in vivo shRNA screen (Fig-
ures 6A and S6A) focused on 19 genes (97 shRNAs), with seven
control shRNAs to maximize the sensitivity of the in vivo readout.
As expected, all of the shRNAs targeting Itgb3 were powerfully
depleted over 2 weeks. In addition, the screen highlighted
multiple key mediators of Itgb3 signaling that are also essential
for leukemia cells in vivo (Figures 6B and S6B). At least two
validated shRNAswere depleted by>10-fold over 2weeks in vivo
for the Syk, Vav1, Rac2, Rhoa, and CD47 genes. Interestingly,
nearly all of these hits have been implicated in hematologic
malignancies, but their activity has not previously been linked
to integrin signaling in this context.
We focused on Syk for three reasons. First, it is directly down-
stream of Itgb3 in megakaryocytes and thus may be directly
related to Itgb3 function in leukemia cells. Second, data from
germline and conditional knockout animals suggest that in
hematopoiesis, although Syk is potentially important for the
function of select differentiated cells, it may be dispensable for
stem cell function (Cornall et al., 2000; Mo´csai et al., 2002;
Wex et al., 2011). Finally, multiple large-scale phase II clinical
trials of the small-molecule SYK inhibitor R406, the activemetab-
olite of the soluble orally available SYK inhibitor fostamatinib
(Braselmann et al., 2006), in idiopathic thrombocytopenic pur-(D and E) Compared with control, leukemia cells carrying Itgb3 shRNAs (GFPhi) ha
of monocytic differentiation with Wright-Giemsa staining (E) after 3 days.
(F) Human ITGB3 shRNAs (ITGB3-35 and ITGB3-37) decrease ITGB3 protein ex
(G) Wright-Giemsa staining of HL-60 and U937 cells carrying ITGB3 shRNAs sho
(H and I) ITGB3 knockdown in HL-60 cells results in increased levels of differentiati
summarized by a single summed score of normalized gene expression (H) and in
and CD14 (I). **p < 0.01. Error bars represent ±SEM.
See also Figure S5 and Table S3.pura and rheumatoid arthritis did not result in significant neutro-
penia among the treatment groups (Bajpai, 2009; Podolanczuk
et al., 2009; Weinblatt et al., 2008). Thus, Syk may, in part,
explain the selectivity of Itgb3 inhibition on leukemia cells.
We demonstrated that individual, validated Syk shRNAs in
GFP-expressing vectors impair leukemia growth in our model
in vivo (Figures 6C, S6C, and S6D). To examine whether Syk is
an essential mediator of Itgb3 activity, we tested whether TEL-
SYK, a constitutively active form of Syk (Kanie et al., 2004), could
rescue the effect of Itgb3 knockdown. Primary murine leukemia
cells were serially transduced with pMIG-TEL-SYK and either
Itgb3-20 or control shRNAs (carrying the puromycin resistance
gene). Transduced cells were selected with puromycin for
2 days, yielding cells that uniformly express the shRNA. A subset
of this cell population also expresses TEL-SYK. Cells were then
transplanted into sublethally irradiated recipients (Figure S6E).
After 2 weeks, the proportion of GFP+ (TEL-SYK+) leukemia cells
was significantly higher in the leukemias coexpressing the Itgb3
shRNA compared with leukemias coexpressing the control
shRNA (Figure 6D). Importantly, as evidenced by the absence
of GFP+ cell expansion in the TEL-SYK plus shLuc control,
TEL-SYK alone did not change the growth properties of the
leukemia cells in vivo. This result reflects the ability of TEL-SYK
fusion to rescue the inhibitory effects of Itgb3 knockdown.
To further confirm the role of Syk in our model, we generated a
gene-expression signature comprised of genes that are upregu-
lated in human leukemia cell lines after treatment with the Syk
inhibitor R406. Using GSEA, we found that, compared with a
control shRNA, primary leukemia cells carrying the Itgb3 shRNAs
significantly increased expression of the R406 treatment signa-
ture (Figure 6E). We then tested the activity of R406 on leukemia
cells from our model using a coculture assay. OP9 mouse bone-
marrow stromal cells were plated in a clear-bottomed, 384-well
plate, and 24 hr later primary leukemia cells were added to the
stromal layer. After 24 hr, R406 or XK469, a topoisomerase II
inhibitor and positive control for cell death (Kakodkar et al.,
2011), were added to the coculture in six doses. After 6 days,
the plates were imaged and dsRed cells were counted. Mirroring
the expected results with XK649, R406 inhibited leukemia cell
growth in a dose-dependent fashion (Figure 6F).
Next, we examined the biochemical connection between
ITGB3 and SYK. To establish the connection in the context of
the MLL-AF9 translocation, we used the Mono-Mac-6 and
MOLM-13 cell lines, both of which carry the MLL-AF9 transloca-
tion (Matsuo et al., 1997; Ziegler-Heitbrock et al., 1988). The cell
lines were transduced with two human ITGB3 shRNAs, selected
in puromycin, and assessed for levels of phosphorylated SYK
(p-SYK). In both cell lines, knockdown of ITGB3 resulted in a
significant reduction of p-SYK as measured by intracellular
phospho-flow (Figures 6G, 6H, S6F, and S6G). Western blotve decreased cell-surface c-Kit expression (D) and showmorphologic evidence
pression in U937 and HL-60 cells relative to a control shRNA (shCT).
w evidence of differentiation compared with control.
on as assessed by both the expression of amyeloid gene-expression signature,
creased cell-surface expression of the myeloid differentiation markers CD11b
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Figure 6. In Vivo Itgb3 Pathway shRNA
Screen Identifies Syk as a Mediator of
Itgb3 Activity
(A) Simplified depiction of the Itgb3/Itgav pathway,
with hits from the Itgb3-targeted screen shown
in red.
(B) A scatterplot of the change in shRNA repre-
sentation in the bone marrow and spleen
compared with input shows high concordance
(R2 > 0.8) and highlights the activity of Itgb3 17, 19,
and 20 shRNAs (red).
(C) Syk and control shRNAs in GFP-expressing
lentivirus were introduced into primary leukemia
cells. The percentage of GFP+ cells was assessed
before transplant and in the bone marrow after
2 weeks of growth in vivo.
(D) Primary leukemia cells in the spleen carrying
pMIG-TEL-SYK (GFP+) increase over time in the
presence of Itgb3-20 but not control shRNAs,
reflecting the ability of TEL-SYK to rescue the
effect of Itgb3 knockdown.
(E) GSEA shows increased expression of a
signature generated from leukemia cell lines
treated with the SYK inhibitor R406 in leukemia
cells with Itgb3 knockdown relative to controls.
(F) Cobblestone area of leukemia cells grown in
coculture on OP9 bone-marrow stromal cells was
evaluated after 7 days of treatment with a topo-
isomerase II inhibitor (XK469, green) or a SYK
inhibitor (R406, red).
(G) Levels of p-SYK in Mono-Mac-6 cells were
determined by intracellular flow cytometry after
introduction of control or ITGB3 shRNAs.
(H) Representative histograms.
(I) ITGB3, p-SYK, and SYK levels were assessed
by western blot analysis in Mono-Mac-6 cells after
infection with shRNAs. *p < 0.05, **p < 0.01. Error
bars represent ±SEM.
See also Figure S6.
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Leukemia-Specific Dependence on Itgb3 Signalinganalysis confirmed that knockdown of ITGB3 reduced levels of
p-SYK without changing overall SYK levels in both cell types
(Figures 6I and S6H). To extend the results beyond MLL-AF9,
we transduced SKM1 cells, originally isolated from a patient
with myelomonocytic leukemia (Nakagawa and Matozaki,
1995), with ITGB3 shRNAs. Western blot analysis again revealed
that both ITGB3 shRNAs caused a powerful decrease in p-SYK
levels without changing the overall SYK levels (Figure S6I),
demonstrating that ITGB3 directly impacts SYK activation in
leukemia cells.
Germline Loss of Itgb3 Selectively Impairs
Leukemogenesis
Finally, to confirm the selective role of Itgb3 in leukemia cells
relative to normal HSPCs, we examined a definitive genetic
model with homozygous germline inactivation of Itgb3. In agree-
ment with the normal peripheral counts previously reported for
the Itgb3 knockout mice (Hodivala-Dilke et al., 1999), we found54 Cancer Cell 24, 45–58, July 8, 2013 ª2013 Elsevier Inc.that there was no difference in the abso-
lute number or percentage of hematopoi-
etic progenitors in the bone marrow of
Itgb3/ and Itgb3+/ groups (Figures
7A, S7A, and S7B). Next, we sought to characterize the effect
of germline Itgb3 loss on HSPCs using long-term competitive
reconstitution assays. One million bone marrow cells from either
Itgb3/ or littermate control Itgb3+/+ mice (CD45.2) were
transplanted along with one million wild-type competitor bone-
marrow cells (CD45.1/2) into lethally irradiated recipient mice
(CD45.1; Figure S7C). We assessed the chimerism of the
hematopoietic compartment over 22 weeks by comparing
CD45.1, CD45.1/2, and CD45.2 levels in the peripheral blood.
There was no difference in the levels of chimerism between
Itgb3/ and Itgb3+/+ bone marrow (Figure 7B), indicating that
germline loss of Itgb3 does not impair the ability of normal
HSPCs to home, engraft, or grow in a long-term in vivo transplan-
tation assay. Finally, we analyzed the distribution of differenti-
ated cells in recipient mice that received either Itgb3/ and
Itgb3+/+ bone marrow, and found that peripheral blood lineage
analysis at 22 weeks showed no difference in the levels of
myeloid (Mac1+Gr1+), T cell (CD3+), or B cell (B220+) levels
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Figure 7. Germline Loss of Itgb3 Selectively
Impairs Leukemogenesis
(A) Bone-marrow immunophenotypic analysis re-
veals no difference in the frequency of different
hematopoietic progenitor populations between
Itgb3/ and Itgb3+/ mice.
(B) There is no difference between Itgb3/ and
Itgb3+/+ hematopoietic stem cell function in long-
term competitive transplant assays, as evidenced
by peripheral blood chimerism (n = 6 each group)
at 22 weeks.
(C) Recipient mice transplanted with bone marrow
from either Itgb3/ or Itgb3+/+ mice show no dif-
ference in the levels of differentiated cells in the
peripheral blood after 22 weeks.
(D) Bone marrow from littermate Itgb3/ (blue)
and Itgb3+/+ (green) mice were enriched for c-Kit+
cells using magnetic beads, infected with pMSCV-
MLL-AF9-IRES-GFP, and transplanted into
lethally irradiated recipient mice. Mice trans-
planted with the Itgb3/ transduced cells lived
significantly longer. Error bars represent ±SEM.
See also Figure S7.
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Leukemia-Specific Dependence on Itgb3 Signalingbetween the two groups (Figure 7C). Thus, loss of Itgb3 by germ-
line deletion or by shRNA knockdown does not impair normal
HSPC engraftment, reconstitution, or differentiation.
Given the dramatic growth-inhibitory effect of Itgb3 shRNAs
on leukemia cells in vivo, we examined the effect of expressing
the MLL-AF9 fusion gene in Itgb3/ cells. We hypothesized
that if Itgb3 is required for leukemia growth, there should be an
impairment in the leukemia formation of bone marrow from
Itgb3/ mice carrying MLL-AF9. We tested this directly in an
in vivo leukemogenesis latency experiment. c-Kit+ bone-marrow
cells from either Itgb3/ or littermate control Itgb3+/+ mice were
transduced with pMSCV-MLL-AF9-IRES-GFP retrovirus and
transplanted into lethally irradiated wild-type recipient mice (Fig-
ure S7D). We found that mice transplanted with transduced
Itgb3/ bone marrow lived significantly longer than those trans-
planted with the transduced Itgb3+/+ bone marrow (Figure 7D).
The striking differences observed between malignant and
normal hematopoiesis using both RNAi and germline knockout
studies demonstrate the selective importance of Itgb3 in leuke-
mia and its potential as a therapeutic target.
DISCUSSION
Integrins play a role in multiple cellular processes relevant to
cancer, including homing, adhesion, motility, proliferation, and
apoptosis (Desgrosellier and Cheresh, 2010; Guo and Giancotti,
2004). Using a series of in vivo genetic screens, we identified
Itgb3 as a gene that is selectively functionally essential formurineCancer Cell 24,and human leukemia cells relative to
normal HSPCs. Loss of Itgb3 in leukemia
cells by both RNAi and germline deletion
impaired leukemia cell growth but had
no effect on normal HSPCs in vivo. Leu-
kemia cells carrying an Itgb3 shRNA
were depleted by >50-fold in <2 weeks,
whereas normal HSPCs carrying thesame shRNA were unaffected after 24 weeks. Leukemia cells
from both theM9 leukemiamodel and primary leukemia samples
carrying ITGB3 shRNAs also exhibited impaired growth in vivo.
Moreover, we found leukemia cells to be dependent on Itgav,
the heterodimeric partner of Itgb3; Syk, a kinase downstream
of Itgb3; and genes encoding other interacting proteins or down-
stream signaling molecules. Knockdown of Itgb3 impaired
homing of primary leukemia cells and induced myeloid differen-
tiation in our murine model and in two human leukemia cell line
models, in addition to causing decreased levels of p-SYK in
MLL and non-MLL contexts. In contrast, genetic loss of Itgb3
in normal hematopoietic cells did not impair stem or progenitor
cell function or differentiation in the primary transplant model,
highlighting a potential mechanism by which Itgb3 inhibition
selectively impairs leukemia cell growth.
We identified multiple members of the Itgb3 signaling pathway
that are also essential for leukemia, including Syk, Vav1, Rac2,
Rhoa, Ptk2b, Pak6, and CD47. Knockdown of Syk or small-
molecule Syk inhibition impaired leukemia cell growth, activated
SYK rescued the effects of Itgb3 knockdown, and ITGB3 down-
regulation decreased p-SYK levels. Of note, small-molecule SYK
inhibitors have shown activity against AML in xenotransplant
models, again highlighting the biological and therapeutic
connection between Itgb3 and Syk (Hahn et al., 2009).
The identification of Itgb3 highlights the utility of in vivo genetic
screens for discovering potential therapeutic targets in a physi-
ologic microenvironment. In addition, we employed pooled
in vivo shRNA screens to genetically dissect human cancer cells45–58, July 8, 2013 ª2013 Elsevier Inc. 55
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Leukemia-Specific Dependence on Itgb3 Signalingin a xenotransplantation model and systematically examine the
members of a biological pathway. The screens are quantitative,
using massively parallel sequencing with thousands of reads per
shRNA, and are highly robust, with the same shRNAs scoring
across replicates, tissues (bone marrow and spleen), and
different pooled screens.
Our findings highlight a critical axis for the biology and treat-
ment of AML. The identification of the leukemia-selective depen-
dence on Itgb3, confirmation of ITGB3’s importance in human
disease, molecular dissection of Itgb3 signaling, and elucidation
of the cellular programs influenced by Itgb3 highlights the
significance of this pathway for therapeutic interventions. Our
studies also provide a paradigm for incorporating physiologically
relevant screening strategies to further drive biological and
drug-discovery efforts for this and other highly aggressive
malignancies.
EXPERIMENTAL PROCEDURES
Lentiviral and Retroviral Production, Infection, and Screening
Lentivirally expressed shRNAs in the pLKO.1 backbone vector were obtained
from the RNAi Consortium at the Broad Institute. Production of lentiviral super-
natants was performed as previously described (Luo et al., 2008). Pooled
lentivirus for screening was generated either by pooling equal amounts of
the lentiviral backbone vector DNA prior to lentiviral production or by pooling
titered virus for each individual shRNA to ensure equal representation of
each shRNA. In the murine validation screen, each subpool of 55 shRNAs
was introduced into one million cells, yielding an average of 4,500 cells
infected with each shRNA. See Supplemental Experimental Procedures for
further details regarding the DNA harvesting and sequencing for shRNA repre-
sentation, and a list of shRNAs used in follow-up studies.
Mouse Maintenance and Murine Studies
All mouse experiments were conducted under IUCAC-approved animal proto-
cols at Children’s Hospital Boston. The mouse strains used in this study
included C57BL/6 (Taconic), C57BL/6 Actin-dsRed (Jackson Laboratory),
and NOD-SCID/IL2Rg/ (NSG; Jackson Laboratory). Recipient mice were
either sublethally or lethally irradiated (1 3 5.5 Gy [550 rads] or 2 3 5.5 Gy
[550 rads], respectively) prior to tail vein transplantation, as noted in the text.
Transplanted cells were resuspended in 300 ml Hank’s balanced salt solution
(Lonza) and loaded in 27.5 gauge syringes (Becton Dickinson).
To generate leukemia cells, primary GMPs (Linlo, Sca-1, c-Kit+, Fc?RIIhi,
and CD34hi) were purified from C57BL/6 Actin-dsRed mice using flow
cytometry, transduced with pMSCV-MLL-AF9-Neo, and transplanted into
lethally irradiated C57BL/6 recipients as previously described (Krivtsov
et al., 2006). After disease onset, cells were harvested from the spleens
and transplanted into sublethally irradiated secondary recipients. Transplan-
tation of bulk splenocytes from leukemic secondary mice was subsequently
repeated twice to generate leukemia cells from quaternary transplant
leukemic mouse spleens. See Supplemental Experimental Proceduresfor
the details of isolation and infection of normal leukemia cells for screening
and follow-up studies.
For the Itgb3 knockout studies, c-Kit+ cells from Itgb3/ or littermate con-
trol Itgb3+/+ mice were harvested and transplanted into wild-type recipients
with helper bone marrow as described in the Supplemental Experimental
Procedures. Chimerism analysis was performed using the CD45.1/2 system.
Human Primary Cell Analysis and shRNA Screen
All human studies were performed with informed consent and approval from
the University of Rochester institutional review board. The human shRNA M9
screens in M9 cells (Barabe´ et al., 2007) and cryopreserved AML samples
were performed in sublethally irradiated NSG mice in five replicates. Sample
isolation was performed in a manner analogous to that used for the murine
studies. See Supplemental Experimental Procedures for details of the
culturing, infection, and harvesting protocols.56 Cancer Cell 24, 45–58, July 8, 2013 ª2013 Elsevier Inc.Cell Cycle, Homing, and Differentiation
Cell-cycle analysis of primary leukemia cells was performed 3 days after
lentiviral infection using Hoechst 33342 dye. For the in vivo homing analysis,
cells were isolated 16 hr after transplant from the bone marrow and compared
with input, or analyzed after 24 hr using in vivo two-photon microscopy as
previously described (Fujisaki et al., 2011); see Supplemental Experimental
Procedures for more information. Differentiation analysis of murine leukemia,
HL-60, and U937 was done with Giemsa-Wright staining and flow cytometry
using c-Kit, CD11, and CD14 antibodies.
Gene-Expression Studies
RNAwas isolated using either Trizol or an RNeasy kit (QIAGEN) and cDNAwas
synthesized with SuperScript III (Invitrogen). Gene-expression analysis was
performed on either the MouseWG-6 v2.0 Expression BeadChip (Illumina) or
HT HG-U133A arrays. See Supplemental Experimental Procedures for details
of sample preparation.
Data Analysis and Statistics
Kaplan-Meier analysis was performed using Prism 5 (GraphPad) software. In
all figures, the mean and SEM are shown. For the shRNA screens, the raw
sequencing data were normalized to the total number of reads for each
replicate. The fold change was calculated as the ratio of normalized reads
between two time points, divided by the ratio of read counts of control shRNAs
between the same time points. A gene was considered a hit in the primary
screen, ITGB3 targeting screen, and M9 screen if two shRNAs had a fold
change of >10. For the validation screen, a depletion of 20-fold and enrichment
of 2-fold were used.
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